Get the Stockscreener App
2.47
20.49%
0.42
Pre-market:
2.44
-0.03
-1.21%
Heron Therapeutics Inc stock is traded at $2.47, with a volume of 6.63M.
It is up +20.49% in the last 24 hours and up +45.29% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$2.05
Open:
$1.98
24h Volume:
6.63M
Relative Volume:
2.25
Market Cap:
$375.67M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-15.44
EPS:
-0.16
Net Cash Flow:
$-9.61M
1W Performance:
+42.77%
1M Performance:
+45.29%
6M Performance:
+27.98%
1Y Performance:
-7.14%
1-Day Range:
$1.98
$2.47
1-Week Range:
$1.65
$2.47
52-Week Range:
$1.04
$3.93
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
2.47 | 375.67M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Brokers Offer Predictions for HRTX Q1 Earnings - MarketBeat
Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
D.A. Davidson & CO. Has $57,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by New York State Common Retirement Fund - Defense World
Heron Therapeutics (NASDAQ:HRTX) Stock Rating Upgraded by StockNews.com - Defense World
Heron Therapeutics (NASDAQ:HRTX) Upgraded to Buy at StockNews.com - MarketBeat
Heron Therapeutics' (HRTX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry - Simply Wall St
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2024 Earnings Call Transcript - Insider Monkey
High Growth Tech Stocks to Watch in US Market February 2025 - Yahoo Finance
Heron Therapeutics (NASDAQ:HRTX) shareholders are up 19% this past week, but still in the red over the last five years - Simply Wall St
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by D.A. Davidson & CO. - Defense World
Heron Therapeutics Reports Strong 2024 Financial Results - TipRanks
Heron Therapeutics Inc. Reports Strong Earnings and Strategic Growth - TipRanks
Earnings call transcript: Heron Therapeutics Q4 2024 beats EPS forecast, stock surges - Investing.com Canada
Heron Therapeutics: Q4 Earnings Snapshot - CT Insider
Heron Therapeutics stock soars 21% on earnings beat, strong guidance - Investing.com
Heron Therapeutics stock soars 21% on earnings beat, strong guidance By Investing.com - Investing.com Australia
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
HERON THERAPEUTICS Earnings Results: $HRTX Reports Quarterly Earnings - Nasdaq
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results - TradingView
HERON THERAPEUTICS, INC. /DE/ SEC 10-K Report - TradingView
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates - PR Newswire
Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday - MarketBeat
Heron Therapeutics (HRTX) to Release Quarterly Earnings on Thursday - Defense World
Heron Therapeutics Amends Working Capital Facility Agreement -February 20, 2025 at 03:23 pm EST - Marketscreener.com
Heron Therapeutics extends loan agreement maturity to 2027 - Investing.com
Heron Therapeutics extends loan agreement maturity to 2027 By Investing.com - Investing.com UK
Ratios in Focus: Analyzing Heron Therapeutics Inc (HRTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Heron Therapeutics (NASDAQ:HRTX) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Stock Price Passes Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 - StreetInsider.com
Accomplished CEO eyes another success story in Cary - The Business Journals
Analysts review Heron Therapeutics Inc’s rating - Knox Daily
Heron Therapeutics (NASDAQ:HRTX) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
An analyst sees good growth prospects for Heron Therapeutics Inc (HRTX) - SETE News
Financial Metrics Check: Heron Therapeutics Inc (HRTX)’s Ratios for Trailing Twelve Months - The Dwinnex
Are Heron Therapeutics Inc (HRTX) shares a good deal now? - US Post News
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
StockNews.com Downgrades Heron Therapeutics (NASDAQ:HRTX) to Hold - MarketBeat
JPMorgan Chase & Co. Has $411,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics (NASDAQ:HRTX) Stock Rating Lowered by StockNews.com - Defense World
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):